News

December 8, 2020December 8, 2020

FDA Puts RV001 on Fast Track for Treating Prostate Cancer

News

The U.S. Food and Drug Administration (FDA) has granted fast track status to RV001, RhoVac‘s investigational therapy for prostate cancer, the company announced. Fast track designation helps speed the approval ... Read more

December 3, 2020December 3, 2020

FDA Approves First PSMA-targeted PET Imaging Agent for Prostate Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) as a positron emission tomography or PET imaging agent for men with prostate cancer. The ... Read more

December 1, 2020December 1, 2020

FDA Approves FoundationOne Liquid CDx as Companion Test for Lynparza in mCRPC Patients

News

The U.S. Food and Drug Administration (FDA) has approved FoundationOne Liquid CDx to be used as a companion diagnostic test to identify men with metastatic castration-resistant prostate cancer (mCRPC) who ... Read more

November 26, 2020November 25, 2020

New $100M Program Aims to Improve Diversity in Clinical Trials

News, syndicated

A new $100-million program aims to improve the diversity of participants in U.S. clinical trials with the ultimate goal of achieving better health outcomes and parity in care for underserved patient ... Read more

November 24, 2020November 24, 2020

PCF Helps Fund 2 Centers of Excellence to Treat Veterans With Prostate Cancer

News

The Prostate Cancer Foundation (PCF) has committed $5 million to support the launch of two new Centers of Excellence that will provide precision medicine treatments to veterans with prostate cancer. ... Read more

November 19, 2020November 19, 2020

Puerto Rico to Test miR’s ‘Liquid Biopsy’ in Detecting Prostate Cancers

News

The Puerto Rico Health Insurance Administration (ASES) has signed an agreement with miR Scientific to evaluate the economic and health benefits of using the miR Sentinel PCC4 Assay, also called the ... Read more

November 17, 2020November 17, 2020

AI-enabled Software To Detect Prostate Cancer Bone Metastases Clears FDA

News

An artificial intelligence (AI) program that aims to make it easier to identify bone metastases in men with prostate cancer has been granted 501(k) clearance by the U.S. Food and Drug ... Read more

November 12, 2020November 12, 2020

UK Study to Assess Causes of Greater Prostate Cancer Risk Among Black Men

News

Enrollment has resumed in a five-year U.K. study investigating genetic factors behind the higher risk of prostate cancer in men of African and Caribbean descent. The study involves researchers at ... Read more

November 10, 2020November 10, 2020

European Commission OKs Lynparza for Metastatic CRPC With BRCA Mutations

News

The European Commission has approved Lynparza (olaparib) to treat people with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in the DNA repair genes BRCA1 and BRCA2. The approval follows a positive ... Read more

November 5, 2020November 5, 2020

Hold Lifted on Phase 1 Trial Testing P-PSMA-101 CAR T-cell Therapy in mCRPC

News

A Phase 1 trial evaluating Poseida Therapeutics’ autologous CAR T-cell therapy P-PSMA-101 for metastatic castration-resistant prostate cancer (mCRPC) is resuming immediately, after its clinical hold was lifted. The U.S. Food ... Read more